Ten years of improvement in the management of multiple myeloma: 2000-2010

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 6, 2010, Pages 424-442

  Harousseau, Jean Luc ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Diagnostics; Disease staging; Genetic changes; Pathophysiology; Serum free light chain assay

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTICOAGULANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PAMIDRONIC ACID; PLACEBO; PLERIXAFOR; PREDNISONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DETECTION; ANTICOAGULANT THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCINTISCANNING; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHROMOSOME DISORDER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE DOSAGE; GENE EXPRESSION PROFILING; GERIATRIC PATIENT; HEMATOLOGIC DISEASE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; JAW OSTEONECROSIS; KIDNEY FAILURE; LOW DRUG DOSE; LUNG EMBOLISM; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE MYELOMA; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PROGNOSIS; SOMNOLENCE; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 79952911779     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.076     Document Type: Article

References (199)

1. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47:673-80. (Pubitemid 32275810)
2. Jagannath S. Value of serum free light chain for diagnosis and monitoring of monoclonal gammopathies in hematology. Clin Lymph Myel 2007; 7:518-23. (Pubitemid 350043489)
3. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain an analysis in multiple myeloma and related disorders. Leukemia 2009; 23:215-24.
4. Katzmannn JA, Dispenzieri A. Kyle Ra, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assay. Mayo Clin Proc 2006; 81:1575-8. (Pubitemid 44871901)
5. Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with non secretory multiple myeloma. Blood 2001; 97:2900-2.
6. Durie BG, Harouseau J-L, San Miguel J, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20:1467-73. (Pubitemid 44264086)
7. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of unknown significance. Blood 2005; 111:812-7. (Pubitemid 41076419)
8. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111:785-9.
9. Dingli D, Kyle Ra, Rajkumat SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006; 108:1979-83. (Pubitemid 44395010)
10. Kyrtsonis MC, Vassilakopoulos N, Katasi N, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007; 137:240-3.
11. Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal for immunogloblin free light chain as marker for response. Blood 2008; 111:4908-15.
12. Van Rhee F., Bolejack V, Holllmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110:827-32. (Pubitemid 47267417)
13. Snozek CLH, Katzmann JA, Kyle RA, et al. prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008; 22:1933-7.
14. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107:3378-83.
15. Singhal S, Vickrey E, Krishnamurthy J, et al. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood 2009; 114:38-9.
16. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009; 23:1545-56.
17. Shortt CP, Gleeson TG, Breen KA, et al. Whole-body MRI versus PET in assessment of multiple myeloma activity. AJR Am J Roentgenol 2009; 192:980-6.
18. Lutje S, Deooy JW, Croockewit S, et al. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutic evaluation of patients with multiple myeloma. Ann Hematol 2009; 88:1161-8.
19. Zamagni E, Nanni C, Patriarca P, et al. A prospective comparison of 18F- flurodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007; 92:50-5. (Pubitemid 46232657)
20. Bartel TB, Haessler J, Brown TLY, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009; 114:2068-76.
21. Greipp PR, San Miguel J, Durie BGM, et al. International Staging System for Multiple Myeloma. J Clin Oncol 2005; 23:3412-20.
22. Hari PN, Zhang MJ, Roy V, et al. Is the International Staging System superior to the Durie Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia 2009; 23:1528-34.
23. Smadja NV, Bastard C, Brigaudeau C, et al. fruchart C Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 108:2229-38.
24. Fassas AB, Spencet T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br F Haematol 2002; 118:1041-7. (Pubitemid 35025967)
25. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma:durable complete remission and superior survival in the absence of chromosome 13 deletion. Blood 2000; 95:4008-10. (Pubitemid 30412882)
26. Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities. Cancer Res 2002; 62:715-20.
27. Konigsberg R, Zojer N, Ackermann J, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000; 18:804-12. (Pubitemid 30106611)
28. Shaughnessy J, Jr, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: Early results of total therapy II. Br J Haematol 2003; 120:44-52.
29. Facon T, Avet-Loiseau H, Guillrmen G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97:1566-71. (Pubitemid 32217218)
30. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100:1579-83. (Pubitemid 34925131)
31. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101:4569-75. (Pubitemid 36857829)
32. Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125:64-8. (Pubitemid 38453279)
33. Jaksic W, Trudel S, Chang H, et al. Cliinical outcomes in t(4;14) mutiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005; 23:7069-73.
34. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101:1520-9. (Pubitemid 36182529)
35. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106:2837-40. (Pubitemid 41510761)
36. Chang H, Qi C, Qi-long Y, et al. P53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005; 105:358-60. (Pubitemid 40053104)
37. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109:3489-95. (Pubitemid 46572539)
38. Wu KL, Beverloo B, Lokhorst HM, et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol 2007; 136:615-23. (Pubitemid 46148198)
39. Chang H, Ning Y, Qi X. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol 2007; 139:51-4. (Pubitemid 47389925)
40. Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increased CKS1b expression in myeloma. Leukemia 2006; 20:2034-40. (Pubitemid 44614894)
41. Fonseca R, Bergsagel PL, Drach J, et al. International MyelomaWorking Group molecular classification of multiple myeloma. Spotlight review. Leukemia 2009; 23:2210-21.
42. Shaughnessy JD, Jr, Zhan F, Burington B, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109:2276-84. (Pubitemid 46425864)
43. Zhan F, Barlogie B, Mulligan G, et al. High-risk myeloma:A gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single agent bortezomib or high-dose dexamethasone. Blood 2008; 111:968-9.
44. Decaux O, Lode L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du Myelome. J Clin Oncol 2008; 26:4798-805.
45. Carrasco DR, Tonon G, Huang Y, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007; 11:349-60. (Pubitemid 46518314)
46. Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009; 27:4585-90.
47. Laubach JP, Mahindra A, Mitsiades CS, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009; 23:2222-32.
48. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventionalchemotherapy. Blood 2000; 96:2943-50.
49. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-6. (Pubitemid 32691956)
50. Mitsiades N, Mitisiades CS, Poulaki V, et al. Apoptotic, signalling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells:therapeutic implications. Blood 2002; 99:4525-30. (Pubitemid 34627223)
51. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-71.
52. Richardson P, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-17. (Pubitemid 36741588)
53. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2004; 127:165-71.
54. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108:3458-64.
55. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009; 114:772-8.
56. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasia with thalidomide and its derivates. J Clin Oncol 2003; 21:4444-52.
57. Palumbo A, Facon T, Sonnevevld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111:3968-77.
58. Vacca A, Ribatti D, Ron Cali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87:503-8. (Pubitemid 24230014)
59. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natutal killer activity in multiple myeloma. Blood 2001; 98:210-6.
60. Glasmacher A, Hahn C, Hoffman F, et al. A systematic review of phase- II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132:584-93. (Pubitemid 43381591)
61. Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010; 95:311-9.
62. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide associated thrombosis in myeloma. Leukemia 2008; 22:414-23. (Pubitemid 351255436)
63. Le Blanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62:4996-5000. (Pubitemid 34984425)
64. Mitsiades N, Mitisiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99:14374-9. (Pubitemid 35257679)
65. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-98. (Pubitemid 41007864)
66. Sonneveld P, Richardson PG, Schuster MW, et al. Bortezomib at first relapse is superior to high-dose dexamethasone and more effective that when given later in relapsed multiple myeloma. Haematologica 2005; 90:146-7.
67. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to event results of the APEX trial. Blood 2007; 110:3557-60. (Pubitemid 350159621)
68. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombo cytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106:3777-84. (Pubitemid 41739012)
69. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113-20. (Pubitemid 46638949)
70. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk elderly patients with relapsed multiple myeloma. Br J Haematol 2007; 137:429-35. (Pubitemid 46698286)
71. San Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008; 22:842-9.
72. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109:2604-6. (Pubitemid 46425908)
73. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25:3892-901. (Pubitemid 47477266)
74. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100:3063-7. (Pubitemid 35217050)
75. Weber DM, Chen C, Nievisky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357:2133-42. (Pubitemid 350146108)
76. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357:2123-32. (Pubitemid 350146107)
77. Stadtmauer EA, Weber DM, Niesvitzky R, et al. Lenalidomide in combination with dexamethasone at first relapse in compsrison with its use as salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009; 82:426-32.
78. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008; 112:4445-51.
79. Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009; 146:164-70.
80. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in patients with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007; 47:1466-75. (Pubitemid 350115306)
81. Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010; 115:3807-14.
82. Pineda-Roman M, Zangari M, Van Rhee F., et al. VTD combinations therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008; 22:1419-27. (Pubitemid 352006086)
83. Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood 2007; 109:2767-72. (Pubitemid 46482069)
84. Palumbo A, Larocca A, Falco P, et al Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed or refractory multiple myeloma. Leukaemia 2010; 24:1037-42
85. Richardson PG, Weller E, Jagannath S, et al Multicenter phase I dose escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009; 27:5713-9.
86. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516-20.
87. Harousseau J-L, Moreau P. Autologous stem-cell transplantation in multiple myeloma. N Engl J Med 2009; 360:2645-54.
88. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma. A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007; 13:183-96. (Pubitemid 46112369)
89. Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335:91-7. (Pubitemid 26240110)
90. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-83. (Pubitemid 36532313)
91. Attal M, Harousseau J-L, Facon T, et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495-502. (Pubitemid 38010075)
92. Cavo M, Tosi P, Zamagni E, et al. Prospective randomized study of single compared with double autologous stem cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25:2434-41. (Pubitemid 46999214)
93. Sonneveld P, van der Holt B, Segeren CM, et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple:long-term results of the Dutch Cooperative Group Hovon 24 trial. Haematologica 2007; 92:928-35. (Pubitemid 350144239)
94. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004; 103:20-32. (Pubitemid 38029914)
95. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of Thalidomide plus Dexamethasone compared with Dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431-6. (Pubitemid 46630462)
96. Cavo M. Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethsone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106:35-9. (Pubitemid 40967171)
97. Macro M, Divine M, Uzunban Y, et al. Dexamethasone + thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: a randomized trial. Blood 2006; 108:22a (abstract).
98. Harousseau J.-L., Attal M, Avet-Loiseau H., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28:4621-9.
99. Lokhorst HM, Schidt-Wolf I., Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial remission rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008; 93:124-7. (Pubitemid 351156161)
100. Morgan GJ, Davies FE, Owen RG, et al. Thalidomide combinations improve response rates: results from the MRC IX study. Blood 2007; 110:1051a (abstract).
101. Sonneveld P, Van Der Holt B, Schmidt-Wolf IG, et al. First analysis of Hovon 65/GMMG-HD4 randomized Phase III trial comparing bortezomib, adriamycine,dexamethasone (PAD) vs VAD as induction prior to high dose melphalan in patients with newly diagnosed multiple myeloma. Haematologica 2009; 94: (abstract 473).
102. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexaethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma:an open-label randomized controlled trial. Lancet Oncol 2010; 11:29-37.
103. Einsele H, Liebisch P, Langer C, et al. Velcade, intravenous cyclophosphamide and dexamethasone induction for previously untreated multiple myeloma (German DSMM Xia trial). Blood 2009; 114:59-60 (abstract 130).
104. Cavo M, Tacchetti P, Patriarca F, et al. A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide dexamethasone (TD) for multiple myeloma: Superior clinical outcomes with VTD compared to TD. Blood 2009; 114: (abstract 351).
105. Rosinol L, Cibeira T, Martinez J, et al. Thalidomide/dexamethasone (TD) versus bortezomib (velcade)/thalidomide/dexamethasone (VTD) versus VBMCP/VBAD velcade as induction regimen prior to autologous stem-cell transplantation in multiple myeloma. Results of a phase III Pethema/Gemm trial. Blood 2009; 114:58-9 (abstract 129).
106. Harousseau J.-L., Avet-Loiseau H., Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose of bortezomib plus thalidomide plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed patients with multiple myeloma. Blood 2009; 114:150 (abstract 354).
107. Ludwig H, Viterbo L, Greil R, et al. Bortezomib, thalidomide and dexamethasone (VTD) versus VTD plus cyclophosphamide as induction therapy in previously untreatred multiple myeloma patients elgible for HDY-ASCT: a randomized phase 2 trial. Blood 2009; 114: (abstract 2312).
108. Kumar S, Flin IW, Hari PN, et al. Novel three and four combinations of bortezomib, dexamethasone, cyclophosphamide and lenalidomide for newly diagnosed multiple myeloma: encouraging results from multicenter, randomized, phase 2 Evolution trial. Blood 2009; 114: (abstract 29).
109. Breitkreutz I, Lokhorst HW, Raab MS, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007; 21:1294-9. (Pubitemid 46831819)
110. Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008; 14:795-8. (Pubitemid 351773154)
111. Giralt S, Stadtmauer EA, Harousseau J.-L., et al. International Working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy in multiple myeloma and the role of plerixafor. Leukemia 2009; 23:1904-12.
112. Harousseau JL, Avet-Loiseau H., Attal M, et al. Achieving at least very good partial remission is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy. Long-term results of the IFM 99-02 and 99-94 trials. J Clin Oncol 2009; 27:5720-6.
113. Harousseau J.-L., Attal M, Avet-Loiseau H.. The role of complete remission in multiple myeloma. Blood 2009; 114:3139-46.
114. Lahuerta JJ, Mateos MV, Rosinol L, et al. Influence of pre- and post-transplantation outcomes of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26:5775-82.
115. Harousseau J.-L., Avet-Loiseau H., Attal M, et al. High complete and very good partial remission response rates with bortezomib-dexamethasone as induction prior to ASCT in newly diagnosed patients with high-risk myeloma: results of the IFM 2005-01 phase 3 trial. Blood 2009; 114:149-50 (abstract 353).
116. Moreau P, Facon T, Attal M, et al. Comparison of 200mg/m2 melphalan and 8 Gy total body irradiation plus 140mg/m2 melphalan as conditioning regimen for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma; final analysis of the Intergroupe Francophone du Myelome 95002 randomized trial. Blood 2002; 99:731-5. (Pubitemid 34525530)
117. Palumbo A, Brighen S, Bruno B, et al. Melphalan 200mg/m2 versus melphalan 100mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase II study. Blood 2010; 115:1873-9.
118. Roussel M, Moreau P, Huinh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem-cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010; 115:32-7.
119. The Myeloma Trialists'Collaborative Group. Interferon as therapy for multiple myeloma: metaanalysis of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113:1020-34.
120. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of Phase III US Intergroup trial S9321. J Clin Oncol 2006; 24:929-36. (Pubitemid 46638847)
121. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 15:3289-94.
122. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med 2006; 354:1021-30. (Pubitemid 43357806)
123. Spencer A, Prince HM, Roberts A, et al. Consolidation therapy with thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single ASCT procedure. J Clin Oncol 2009; 27:1788-93.
124. Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase III study on the effect of thalidomide combined with adriamycin, dexamethasone (TAD) and high-dose melphalan followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010; 115:1113-20.
125. Morgan GJ, Jackson GH, Davies FE, et al. Maintenance thalidomide may improve progression free but not overall survival: results from the Myeloma IX maintenance randomization. Blood 2008; 112: (abstract 656).
126. Barlogie B, Pineda-Roman M, Van Rhee F., et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with interphase cytogenetic abnormalities. Blood 2008; 112:2999-3000.
127. Morgan GJ, Davies FR, Gregory WM, et al The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS. Blood 2009; 114: (abstract 352).
128. McCarthy PL, Owzar K, Anderson KC, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplantation for multple myeloma; CALGB 100104. J Clin Oncol 2010; 28(15 suppl):577s (abstract 8017).
129. Attal M, Cristini C, Marit G, et al. Lenalidomide maintenance after transplantation for myeloma. J Clin Oncol 2010; 28(15 suppl):577s (abstract 8018).
130. Barlogie B, Attal M, Crowley J, et al. Long-term follow-up of autologous transplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group and University of Arkansas Medical Sciences. J Clin Oncol 2010; 28:1209-14.
131. Pineda Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3:comparison with total therapy 2. Br J Haematol 2008; 140:625-34. (Pubitemid 351300910)
132. Shaughnessy JD, Zhou Y, Haessler J, et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol 2009; 147:347-51.
133. Harousseau J.-L. The allogeneic dilemma. Bone Marrow Transplant 2207:1123-8.
134. Crawley C, Lalancette M, Szydlo R, et al. Outcomes of reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 105:4532-9. (Pubitemid 40720805)
135. Crawley C, Iacobelli S, Björkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109:3588-94. (Pubitemid 46572554)
136. Rotta M, Storer BE, Sahebi F, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009; 113:3383-91.
137. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356:1110-20. (Pubitemid 46425595)
138. Moreau P, Garban F, Attal M, et al. Long-term follow-up results of IFM 99-03 and IFM 99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008; 112:3914-5.
139. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective Pethema study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in multiple myeloma. Blood 2008; 112:3591-2.
140. Bruno B, Rotta M, Patriarca F, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma:the experience of the Gruppo Intaliano Trapianti di Medolla. Blood 2009; 113:3375-82.
141. Kroger N, Zabelina T, Ayuk T, et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multipe myeloma to enhance or maintain remission status. Exp Hematol 2006; 34:770-5. (Pubitemid 43737100)
142. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111:2521-6.
143. Kyle RA, Rajkumar SV. Multiple Myeloma. N Engl J Med 2004; 351:1860-73.
144. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma. Randomized controlled trial. Lancet 2006; 367:825-31. (Pubitemid 43363369)
145. Palumbo A, Bringhen S, Liberati A, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma:updated results of a randomized, controlled trial. Blood 2008; 112:3107-14.
146. Facon T, Mary JY, Hulin C, et al. Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 307:1209-18. (Pubitemid 47516593)
147. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma; IFM 01/01 trial. J Clin Oncol 2009; 27:3664-70.
148. Wijermans P, Schaafsma M, Termorhuizen et al. Phase III study of the value of thalidomide added to melphalan prednisone in elderly patients with newly diagnosed multiple myeloma: the Hovon 49 study. J Clin Oncol 2010; 28:3160-6.
149. Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010; May 6 [Epub ahead of print].
150. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108:2165-72.
151. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 35:906-17.
152. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the Phase III Vista trial. J Clin Oncol 2010; 28:2258-66.
153. Palumbo A, Falco P, Corradini P, et al. Melphalan, Prednisone, Lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007; 25:4459-65. (Pubitemid 350063804)
154. Palumbo A, Dimopoulos M, Delforge M. A Phase 3 study to determine the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients = 65 years with newly diagnosed myeloma. Hematologica 2010; 95:566 (abstract).
155. Ludwig H, Hajek R, Tothova E, et al. Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2008; 113:3435-42.
156. Jacobus S, Callander N, Siegel D et al Outcome of elderly patients 70 years and older with newly diagnosed myeloma in the ECOG randomized trial of lenalidomide /high-dose dexamethasone versus lenalidomide/ low-dose dexamethasone. Hematologica 2010 95:370 (abstract).
157. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib thalidomide compared with bortezomid, melphalan, prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010; Oct 12 [Epub ahead of print].
158. Mateos MV, Oriol A, Martinez Lopez J, et al. A prospective, randomized trial of Bortezomib, melphalan, prednisone versus bortezomib, thalidomide, prednisone as induction therapy followed by maintenance treatment with bortezomib, thalidomide versus bortezomib, prednisone in elderly patients with untreated multiple myeloma: a randomized trial. Lancet Oncol 2010; 10:934-41.
159. Facon T, Mary JY, Pegourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006; 107:1292-8. (Pubitemid 43242361)
160. Bringhen S, Larocca A, Rossi D et al Efficacy and safety of once weekly bortezomib in multiple myeloma patients. Blood 2010; Aug 31 [Epub ahead of print]
161. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 23:1657-64.
162. Chang JT, Green L. Beitz Renal failure with the use of zoledronic acid. N Engl J Med 2005; 349:1676-9.
163. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jawsassociated with the use of bisphosphonates. A review of 63 cases. J Oral Maxillofac Surg 2004; 62:527-34. (Pubitemid 38542516)
164. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw: clinical features and risk factors. J Clin Oncol 2006; 24:945-52. (Pubitemid 46638849)
165. Kyle RA, Yee GC, Sornefield MR, et al. American Society of Clinical Oncology 2007 clinical practice guidelines update on the role of bisphoposphonates in multiple myeloma. J Clin Oncol 2007; 25:2454-72.
166. Terpos E, Sezer O, Croucher P, et al. The use of bisphosphonates in multiple myeloma:: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 8:1303-17.
167. Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30mg versus 90mg on physical finction in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): A double-blind, randomized controlled trial. Lancet Oncol 2010; 10:973-82.
168. Van De Velde HJ, Xiangyang L, Chen G, et al. Complete response correlates with long-term survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92:1399-406. (Pubitemid 350144158)
169. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma and the impact of novel agents. J Clin Oncol 2010; 28:2612-24.
170. Pineda-Roman M, Bolejack V, Arzoumanian V, et al. Complete response in myeloma extends survival without but not with prior history of monoclonal gammopathy of unknown significance or smouldering disease. Br J Haematol 2006; 13:393-9. (Pubitemid 46046297)
171. Haessler J, Shaughnessy JD, Fenghuang Z, et al. Benefit of complete response in multiple myeloma limited to high-risk groups identified by gene expression profiling. Clin Cancer Res 2007; 13:7073-9. (Pubitemid 350276890)
172. Barlogie B, Van Rhee F., Shaughnessy JD, et al. Making progress in treating multiple myeloma with total therapies: issue of complete remission and more. Leukemia 2008; 22:1633-6.
173. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000; 18:2273-81. (Pubitemid 30350220)
174. Corradini P, Cavo M, Lofhirst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predict for a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102:1927-9. (Pubitemid 37022595)
175. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometry is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112:4017-40.
176. Harousseau JL, Dimopoulos MA, Wang M, et al. The quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcome in patients with relapsed or refractory myeloma. Haematologica 2010; May 11 [Epub ahead of print].
177. Harousseau JL, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 2010; Jul 13 [Epub ahead of print].
178. Blade J, Samson D, Reece D, et al. Criteria for evaluating response and progression in patients treated with high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol 1998; 102:1115-23. (Pubitemid 28435189)
179. Avet-Loiseau H., Leleu X, Roussel M. Bortezomib plus dexamethasone induction improves outcome of patients with t(4:14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010; 28:4630-4.
180. Avet-Loiseau H., Soulier J, Fermand JP, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010; 24:623-8.
181. Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone:adverse effect of deletion 17p13. Blood 2009; 114:522-5.
182. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009; 114:518-21.
183. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin/Revlimid/ Dexamethasone) combination therapy results in high complete and overall response rates in treatment-naïve symptomatic multiple myeloma. Blood 2008; 111:1101-9. (Pubitemid 351213388)
184. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib and dexamethasone combination therapy in newly diagnosed multiple myeloma. Blood 2010; 116:679-86.
185. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan (100mg/m2) improves survival of myeloma patients aged 50-70: results of a randomized controlled trial. Blood 2004; 104:3052-7. (Pubitemid 39507119)
186. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation- maintenance in untreated multiple myeloma patients. J Clin Oncol 2010; 28:800-7.
187. Mellqvist UH, Westin J, Gimsing P, et al. Improved response rate with consolidation after high-dose melphalan: first results of a Nordic Myeloma Study Group randomized Phase III TRIAL 536. Blood 2009; 114: (abstract).
188. Attal M, Harousseau J.-L. Marit G, et al. Lenalidomide after autologous transplantation for myeloma. First analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 2005602). Blood 2009; 114: (abstract 529).
189. Ladetto M, Pagliano G, Ferrero, et al. Major shrinking and persistant molecular remissions after consolidation with bortezomib, thalidomide and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28:2077-84.
190. Schey SA, Fields P, Bartlett JD, et al. Phase I study of an immunomulating thalidomide analog CC-3047 in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 32:3269-76. (Pubitemid 41103682)
191. Lacy MQ, Haymann SR, Gertz MA, et al. Pomalidomied (CC4047) plus low-dose dexamethasone therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27:5008-14.
192. Lacy M, Gertz MA, Haymann SR, et al. Activity of pomalidomide plus dexamethasone in dual lenalidomide/bortezomib refractory multiple myeloma. J Clin Oncol 2010; 28(15 suppl):573s (abstract 8002).
193. O'Connor OA, Stewart AK, Vallone M, et al. A phase I dose escalation study of the safety and pharmacokinetics of the novel proteasome-inhibitor carfilzomib (PP171) in patients with hematologic malignancies. Clin Cancer Res 2009; 15:7085-91.
194. Vij R, Siegel DS, Kaufmann JL, et al. Results of an ongoing open-label phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol 2010; 28(15 suppl):573s (abstract 8000).
195. Stewart AK. Novel therapies for relapsed myeloma. ASH Educationnal Program 2009:578-86.
196. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkyl-phospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107:4053-62. (Pubitemid 43726814)
197. Tai YT, Dillon M, Song W, et al. Anti CS1 humanized monoclonal antibody HuLuc 63 inhibits myeloma cell adhesion, and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008; 112:1329-37.
198. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101:4055-62. (Pubitemid 36857886)
199. Ocio EM, Villanova D, Atadja P, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH 589) and dexamethasone plus either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010; 95:794-803.